Navigating the road toward optimal initial therapy for chronic myeloid leukemia
Ross A Okimoto1, Richard A Van Etten
1Division of Hematology/Oncology, Tufts Medical Center, Boston, Massachusetts 02111, USA.
Current Opinion in Hematology
|January 22, 2011
Summary
Tyrosine kinase inhibitors (TKIs) are now the standard for chronic myeloid leukemia (CML) treatment. Newer TKIs show improved response rates but require further study for long-term survival differences.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Tyrosine kinase inhibitors (TKIs) have transformed chronic myeloid leukemia (CML) treatment, replacing older therapies like interferon and stem cell transplantation.
- Currently, imatinib, nilotinib, and dasatinib are FDA-approved for front-line CML therapy, with bosutinib potentially gaining approval.
Purpose of the Study:
- To review the latest information on initial CML treatment strategies.
- To assist clinicians in managing patients newly diagnosed with CML.
Main Methods:
- Review of recent Phase III clinical trial data comparing imatinib with second-generation TKIs (nilotinib, dasatinib).
- Analysis of accelerated FDA approvals for new TKIs in CML treatment.
Main Results:
- Second-generation TKIs demonstrate significant differences in response rates, progression-free survival, and side-effect profiles compared to imatinib.
- While short-term outcomes vary, no significant differences in overall survival have been observed yet.
- Updated guidelines for monitoring CML patients on TKI therapy are now available.
Conclusions:
- Future CML management will involve individualized therapy based on patient factors, similar to antibiotic treatment for infections.
- Therapeutic cost will become a more significant factor, especially with the advent of generic imatinib.
- Further clinical trials are essential to guide optimal treatment decisions for newly diagnosed CML patients.
